The Role of Extended Release Guanfacine in the Management of ADHD - Abstract
Guanfacine extended release (GXR) is a a2A-adrenoreceptor agonist approved by the European Medicines Agency (EMA) in September 2015 for treatment of attention-deficit/hyperactivity disorder (ADHD) in child and young people (CYP) aged 6–17 year, when stimulants are not effective or are not a good choice for patients and/or families. The EMA suggests that GXR should be a part of a multimodal approach to ADHD, with psycho educational support. The present article reviews the chemical, pharmacodynamics, and pharmacokinetics properties of GXR and discussed the results of randomized controlled trials on treatment of ADHD in CYP. The scientific literature supports GXR as good option for ADHD in youth for its safety and efficacy.